Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.urology.2009.07.1289
DC FieldValue
dc.titleComparison of the UCLA Integrated Staging System and the Leibovich Score in Survival Prediction for Patients With Nonmetastatic Clear Cell Renal Cell Carcinoma
dc.contributor.authorTan, M.-H.
dc.contributor.authorKanesvaran, R.
dc.contributor.authorTan, H.L.
dc.contributor.authorTeh, B.T.
dc.contributor.authorChia, K.S.
dc.contributor.authorLi, H.
dc.contributor.authorTan, P.H.
dc.contributor.authorWong, C.F.
dc.contributor.authorChong, T.W.
dc.contributor.authorYuen, J.
dc.date.accessioned2011-07-26T03:01:20Z
dc.date.available2011-07-26T03:01:20Z
dc.date.issued2010
dc.identifier.citationTan, M.-H., Kanesvaran, R., Tan, H.L., Teh, B.T., Chia, K.S., Li, H., Tan, P.H., Wong, C.F., Chong, T.W., Yuen, J. (2010). Comparison of the UCLA Integrated Staging System and the Leibovich Score in Survival Prediction for Patients With Nonmetastatic Clear Cell Renal Cell Carcinoma. Urology 75 (6). ScholarBank@NUS Repository. https://doi.org/10.1016/j.urology.2009.07.1289
dc.identifier.issn00904295
dc.identifier.issn15279995
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/24591
dc.description.abstractObjectives: To directly compare the models-the UCLA-Integrated Scoring System (UISS) and the Leibovich models-using various survival endpoints. Several Phase III trials of adjuvant therapy in renal cell carcinoma (RCC) have been initiated after advances in targeted therapy. To select patients at high risk of relapse and mortality, 2 aforementioned prognostic models have been incorporated into these trials. These models have not been compared previously. Methods: A retrospective study of 355 patients with unilateral nonmetastatic clear cell RCC undergoing nephrectomy between 1990 and 2006 at the Singapore General Hospital was undertaken. Performance of the UISS and the Leibovich models, as well as corresponding trial inclusion criteria, was directly compared using log-likelihood statistics. Adequacy and concordance indices were also calculated. Study endpoints tested were overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Results: Likelihood ratio testing demonstrated a significant benefit in prediction when adding the Leibovich model to the UISS model in all outcomes tested, with no benefit using the converse approach (OS: P = .002 vs P = .27; CSS: P = .0001 vs P = .57; DFS: P = <0.0001 vs P = .30). Benefit was seen primarily in disease-free survival when adding the Leibovich trial criteria to UISS trial criteria, with no benefit using the converse approach (OS: P = .16 vs P = .27; CSS: P = .17 vs P = .11; DFS: P = .01 vs P = .26). Conclusions: Both the Leibovich model and trial criteria are superior to the UISS model and trial criteria, respectively, in estimating survival outcomes in patients with nonmetastatic clear cell RCC after nephrectomy. © 2010 Elsevier Inc. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.urology.2009.07.1289
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentEPIDEMIOLOGY & PUBLIC HEALTH
dc.contributor.departmentDUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE
dc.contributor.departmentPATHOLOGY
dc.description.doi10.1016/j.urology.2009.07.1289
dc.description.sourcetitleUrology
dc.description.volume75
dc.description.issue6
dc.identifier.isiut000278221100035
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

29
checked on Nov 29, 2021

WEB OF SCIENCETM
Citations

25
checked on Nov 22, 2021

Page view(s)

273
checked on Nov 18, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.